The question of whether allogeneic chimeric antigen receptor (CAR) T cells could replace autologous CAR T cell therapy has garnered considerable interest, but limited data have been available for comparisons to date. Now, Benjamin et al. have reported their experience with allogeneic anti-CD19 CAR T cells in 21 paediatric and adult patients with acute lymphoblastic leukaemia.
This is a preview of subscription content, log in via an institution to check access.
References
Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).
Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).
Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020).
Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020).
Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885–1894 (2020).
Qasim, W. et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci. Transl Med. 9, eaaj2013 (2017).
Gattinoni, L. et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J. Clin. Invest. 115, 1616–1626 (2005).
Tumeh, P. C. et al. The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J. Immunother. 33, 759–768 (2010).
Ghassemi, S. et al. Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol. Res. 6, 1100–1109 (2018).
Neelapu, S. S. et al. First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. J. Clin. Oncol. 38 (Suppl. 15), 8002 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.A.G. has received research support from CRISPR/Vertex, Kite/Gillead, Novartis and Servier, and has been a scientific advisory board or steering committee member and/or consultant for Adaptimmune, Allogene, CBMG, Cabaletta, Cellectis, CRISPR/Vertex, GSK, Janssen/Johnson & Johnson, Juno, Jazz, Novartis, Roche and TCR2. A.D. declares no competing interests.
Rights and permissions
About this article
Cite this article
DiNofia, A.M., Grupp, S.A. Will allogeneic CAR T cells for CD19+ malignancies take autologous CAR T cells ‘off the shelf’?. Nat Rev Clin Oncol 18, 195–196 (2021). https://doi.org/10.1038/s41571-021-00485-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00485-1
- Springer Nature Limited
This article is cited by
-
Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice
Nature Communications (2023)
-
Strategies to enhance CAR-T persistence
Biomarker Research (2022)
-
Engineered cellular immunotherapies in cancer and beyond
Nature Medicine (2022)
-
Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy
Nature Reviews Clinical Oncology (2021)